Good, bad or ugly, we need to know about P6P6 may not be relevant to any discussion, but by updating us on the status of P5, I think TLT owes us an explanation of what happened to P6.
We fully understand that any updates beyond 12-month response are completely at the discretion of Theralase, meaning the company had no obligation to report on the 18-month status of patient 5. Having done so, however, it would now seem appropriate for TLT to issue a similar report on patient 6.
In the absence of such report, we will be left speculating with much uncertainty as to fate of patient. Whether its relevant here or not, you can be sure the market loathes uncertainty.